Key facts
- It has raised $284.2M; the latest was Later Stage VC in Dec 2025.
- Notable investors include Shenzhen Capital Group, Korea Investment Partners, GL Ventures, IDG Capital, Qianhai FoF — 16 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 16 names
- ·Watchlist + deal alerts for Maxvax Health
- ·The full record, as it builds
Funding rounds
No funding rounds for Maxvax Health are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Maxvax Health
Developer of rotavirus, shingles and herpes vaccine technology intended to serve the biotechnology industry. The company's vaccines aim to provide effective treatment for viral diseases, enabling healthcare professionals to deliver better treatments to their patients.
- Sector
- Healthcare
- HQ
- Chengdu, China
- Founded
- 2016
- Employees
- 300
- Website
- maxvax.cn/
- Ownership
- Privately Held (backing)
Maxvax Health doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Maxvax Health shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Maxvax Health in its N-PORT filings yet. We sweep new filings monthly.